ABSTRACT
Background and objectives Retinal vein occlusion (RVO) is the second most frequent cause of retinal vascular disease and is related to classic cardiovascular risk factors. A specific program was designed to detect and treat risk factors in patients with RVO. The aim of this study is to audit the results of this program. Patients and methods The program consisted of a multidisciplinary clinical evaluation by the Ophthalmology and Internal Medicine Departments. All patients with RVO were screened, at minimum, for hypertension, diabetes, dyslipidemia, smoking, overweight, and antiphospholipid syndrome. New risk factors or poor control of known risk factors were expected to be found in at least one-third of the patients. Among them, therapeutic measures were expected to be taken in at least two-thirds. A dissociated automated search of the data of all patients who entered the program between April 2021 and April 2022 was performed. Results Fifty-six patients were included for analysis. Of these, 39 (69.6%) had at least one new or poorly controlled risk factor and 43 (76.8%) had their treatment modified in some way. Antiphospholipid syndrome was detected in five (8.9%). Only one patient had low-risk hereditary thrombophilia. After an exhaustive examination, no risk factors were found in 11 patients. Conclusion This specific program has been effective in detecting new or poorly controlled risk factors and improving their treatment (AU)
Antecedentes y objetivo La trombosis venosa de retina (TVR) es la segunda causa más frecuente de enfermedad vascular de la retina y se relaciona con factores de riesgo cardiovascular clásicos. Se diseñó un programa específico para detección y tratamiento de factores de riesgo en pacientes con TVR. El objetivo de este estudio es auditar los resultados de dicho programa. Pacientes y métodos El programa consistió en una evaluación clínica multidisciplinar por parte de Oftalmología y Medicina Interna. A todos los pacientes con TVR se les realizó cribado, al menos, de hipertensión arterial, diabetes, dislipidemia, tabaquismo, sobrepeso y síndrome antifosfolípido. Se esperó encontrar nuevos factores de riesgo o pobre control de los ya conocidos en, al menos, un tercio de los pacientes. Entre ellos, se esperó tomar alguna medida terapéutica en, al menos, dos tercios. Se llevó a cabo una búsqueda automatizada disociada de los datos de todos los pacientes que entraron en el programa entre abril de 2021 y abril de 2022. Resultados Cincuenta y seis pacientes se incluyeron para el análisis. De ellos, 39 (69,6%) tenían al menos un factor de riesgo nuevo o mal controlado, y 43 (76,8%) vieron modificado en algún modo su tratamiento. Se detectó síndrome antifosfolípido en 5 (8,9%). Solo un paciente tenía una trombofilia hereditaria de bajo riesgo. Tras un examen exhaustivo no se encontró factor de riesgo alguno en 11 pacientes. Conclusión Este programa específico ha sido efectivo para detectar factores de riesgo nuevos o mal controlados y mejorar su tratamiento (AU)
Subject(s)
Humans , Male , Female , Middle Aged , Aged , Aged, 80 and over , Retinal Vein Occlusion/etiology , Retinal Vein Occlusion/therapy , Quality Improvement , Medical Audit , Risk FactorsABSTRACT
BACKGROUND AND OBJECTIVES: Retinal vein occlusion (RVO) is the second most frequent cause of retinal vascular disease and is related to classic cardiovascular risk factors. A specific program was designed to detect and treat risk factors in patients with RVO. The aim of this study is to audit the results of this program. PATIENTS AND METHODS: The program consisted of a multidisciplinary clinical evaluation by the Ophthalmology and Internal Medicine Departments. All patients with RVO were screened, at minimum, for hypertension, diabetes, dyslipidemia, smoking, overweight, and antiphospholipid syndrome. New risk factors or poor control of known risk factors were expected to be found in at least one-third of the patients. Among them, therapeutic measures were expected to be taken in at least two-thirds. A dissociated automated search of the data of all patients who entered the program between April 2021 and April 2022 was performed. RESULTS: Fifty-six patients were included for analysis. Of these, 39 (69.6%) had at least one new or poorly controlled risk factor and 43 (76.8%) had their treatment modified in some way. Antiphospholipid syndrome was detected in five (8.9%). Only one patient had low-risk hereditary thrombophilia. After an exhaustive examination, no risk factors were found in 11 patients. CONCLUSION: This specific program has been effective in detecting new or poorly controlled risk factors and improving their treatment.
Subject(s)
Antiphospholipid Syndrome , Hypertension , Retinal Vein Occlusion , Thrombophilia , Humans , Retinal Vein Occlusion/diagnosis , Retinal Vein Occlusion/epidemiology , Retinal Vein Occlusion/etiology , Antiphospholipid Syndrome/complications , Antiphospholipid Syndrome/diagnosis , Antiphospholipid Syndrome/therapy , Thrombophilia/complications , Risk FactorsABSTRACT
Magnetic porous silicon flakes (MPSF) were obtained from mesoporous silicon layers formed by multi-step anodization and subsequent composite formation with Fe oxide nanoparticles by thermal annealing. The magnetic nanoparticles adhered to the surface and penetrated inside the pores. Their structure evolved as a result of the annealing treatments derived from X-ray diffraction and X-ray absorption analyses. Moreover, by tailoring the magnetic load, the dynamic and hydrodynamic properties of the particles were controlled, as observed by the pressure displayed against a sensor probe. Preliminary functionality experiments were performed using an eye model, seeking potential use of MPSF as reinforcement for restored detached retina. It was observed that optimal flake immobilization is obtained when the MPSF reach values of magnetic saturation >10(-4)Am(2)g(-1). Furthermore, the MPSF were demonstrated to be preliminarily biocompatible in vitro. Moreover, New Zealand rabbit in vivo models demonstrated their short-term histocompatibility and their magnetic functionality as retina pressure actuators.
Subject(s)
Intraocular Pressure/physiology , Magnetite Nanoparticles/chemistry , Retina/physiology , Silicon/chemistry , Transducers, Pressure , Animals , Equipment Design , Equipment Failure Analysis , Heating , Magnetic Fields , Porosity , RabbitsABSTRACT
Mujer de 64 años, agudeza visual en ojo derecho (OD) 0,5 y 0,7 en ojo izquierdo (OI). Pseudofaquia bilateral. No signos inflamatorios. PIO normal. Funduscópicamente en la retinografía el OD evidencia un depósito subfoveal amarillento, redondeado, sobreelevado y autofluorescente. Abundantes drusas ecuatoriales y pliegues coroideos bilaterales. En angiofluoresceinografía, el OD muestra hipofluorescencia foveal inicial con hipercaptación tardía. La tomografía de coherencia óptica muestra un depósito hiperrefringente sobre epitelio pigmentario foveal. Campos visuales, ecografías oculares y electrooculogramas: normales. Alteración inespecífica del test de colores. Conclusión: Las distrofias maculares viteliformes y los pliegues coroideos son entidades poco frecuentes y su asociación es excepcional(AU)
A 64 year old woman. Best corrected acuity right eye (RE) 0.5 and 0.7 left eye (LE). Bilateral pseudophakia. No inflammatory signs. Normal IOP. RE fundus showed a rounded, yellow and excessive subfoveal deposit with positive autofluorescence. Multiple equatorial drusen and choroidal folds in both eyes. Fluorescein angiography of RE showed early foveal hypofluorescence and delayed hyperluorescence. Optical coherence tomography revealed a hiperreflective deposit over the foveal epithelium pigment. Visual fields, ocular ultrasounds and electrooculograms were normal. Non-specific alterations in colour tests. Conclusión: Vitelliform maculopathy and choroidal folds are very rare diseases and, exceptionally, appear together(AU)
Subject(s)
Humans , Female , Vitelliform Macular Dystrophy/complications , Vitelliform Macular Dystrophy/diagnosis , Vitelliform Macular Dystrophy/therapy , Fluorescein Angiography , Choroid/injuries , Tomography, Optical Coherence , Fundus OculiABSTRACT
CLINICAL CASE: A 64 year old woman. Best corrected acuity right eye (RE) 0.5 and 0.7 left eye (LE). Bilateral pseudophakia. No inflammatory signs. Normal IOP. RE fundus showed a rounded, yellow and excessive subfoveal deposit with positive autofluorescence. Multiple equatorial drusen and choroidal folds in both eyes. Fluorescein angiography of RE showed early foveal hypofluorescence and delayed hyperluorescence. Optical coherence tomography revealed a hiperreflective deposit over the foveal epithelium pigment. Visual fields, ocular ultrasounds and electrooculograms were normal. Non-specific alterations in colour tests. CONCLUSION: Vitelliform maculopathy and choroidal folds are very rare diseases and, exceptionally, appear together.
